| 2026 |
| 10/02 | 2,813 | 2,832 | 2,766 | 2,786 | -2.31% | 3,322,400 | - | -4% |
| 10/01 | 2,850 | 2,878 | 2,805 | 2,852 | -0.66% | 2,743,400 | - | -1.89% |
| 09/30 | 2,827 | 2,883 | 2,808 | 2,871 | +1.13% | 3,565,700 | - | -1.34% |
| 09/29 | 2,877 | 2,885 | 2,822 | 2,839 | -2.71% | 2,838,900 | - | -2.51% |
| 09/28 | 2,924 | 2,956 | 2,915 | 2,918 | -0.68% | 3,096,000 | - | +0.1% |
| 09/25 | 2,940 | 2,963 | 2,929 | 2,938 | +0.69% | 2,423,900 | - | +0.86% |
| 09/24 | 2,945 | 2,958 | 2,915 | 2,918 | -1.25% | 3,084,900 | - | +0.31% |
| 09/18 | 2,971 | 2,985 | 2,947 | 2,955 | -0.94% | 3,861,900 | - | +1.76% |
| 09/17 | 2,917 | 2,988 | 2,902 | 2,983 | +3.15% | 2,058,600 | - | +2.9% |
| 09/16 | (IR情報)15:00 「ブイタマークリーム」の国内における小児(12歳未満)アトピー性皮膚炎に対する用法・用量追加の製造販売承認取得について |
| 09/16 | (IR情報)15:00 組み換えタンパクワクチン「コブゴーズ筋注」の国内における一部変更承認の取得について |
| 09/16 | 2,888 | 2,918 | 2,871 | 2,892 | -0.41% | 2,366,600 | - | -0.03% |
| 09/15 | 2,914 | 2,948 | 2,900 | 2,904 | +1.75% | 2,690,100 | - | +0.48% |
| 09/14 | 2,840 | 2,862 | 2,818 | 2,854 | +0.96% | 1,950,100 | - | -1.14% |
| 09/11 | 2,819 | 2,834 | 2,791 | 2,827 | -0.14% | 3,364,400 | - | -2.04% |
| 09/10 | 2,832 | 2,847 | 2,808 | 2,831 | -0.56% | 2,442,700 | - | -1.91% |
| 09/09 | 2,885 | 2,892 | 2,846 | 2,847 | -1.76% | 2,897,500 | - | -1.25% |
| 09/08 | 2,923 | 2,926 | 2,888 | 2,898 | -1.53% | 2,177,900 | - | +0.63% |
| 09/07 | 2,942 | 3,005 | 2,928 | 2,943 | +1.17% | 3,526,800 | - | +2.19% |
| 09/04 | 2,946 | 2,968 | 2,904 | 2,909 | -2.77% | 3,499,800 | - | +1.08% |
| 09/03 | 2,980 | 3,026 | 2,968 | 2,992 | +0.34% | 2,843,600 | - | +3.74% |
| 09/02 | 2,963 | 3,005 | 2,939 | 2,982 | +1.08% | 3,320,400 | - | +3.29% |
| 09/01 | 2,909 | 2,963 | 2,907 | 2,950 | +1.34% | 2,264,800 | - | +2.29% |
| 08/31 | 2,880 | 2,918 | 2,871 | 2,911 | -0.07% | 3,008,500 | - | +1.04% |
| 08/28 | 2,891 | 2,927 | 2,891 | 2,913 | +0.1% | 1,463,300 | - | +1.18% |
| 08/27 | 2,906 | 2,934 | 2,886 | 2,910 | -0.48% | 1,519,200 | - | +1.15% |
| 08/26 | 2,932 | 2,965 | 2,908 | 2,924 | +0.45% | 1,772,900 | - | +1.7% |
| 08/25 | 2,940 | 2,960 | 2,911 | 2,911 | -0.38% | 1,506,900 | - | +1.29% |
| 08/24 | 2,920 | 2,961 | 2,912 | 2,922 | +0.1% | 1,550,400 | - | +1.71% |
| 08/21 | 2,932 | 2,951 | 2,912 | 2,919 | -0.48% | 2,335,100 | - | +1.71% |
| 08/20 | 2,905 | 2,945 | 2,897 | 2,933 | +2.59% | 2,628,000 | - | +2.3% |
| 08/19 | 2,881 | 2,881 | 2,819 | 2,859 | +0.99% | 2,447,000 | - | -0.14% |
| 08/18 | 2,800 | 2,842 | 2,789 | 2,831 | +1% | 2,106,300 | - | -1.08% |
| 08/17 | 2,851 | 2,851 | 2,791 | 2,803 | -1.02% | 1,669,800 | - | -2.06% |
| 08/14 | 2,848 | 2,851 | 2,810 | 2,832 | +0.46% | 2,184,400 | - | -1.08% |
| 08/13 | 2,837 | 2,848 | 2,793 | 2,819 | -0.07% | 3,351,900 | - | -1.61% |
| 08/12 | 2,797 | 2,834 | 2,786 | 2,821 | -0.74% | 3,478,600 | - | -1.64% |
| 08/10 | 2,822 | 2,863 | 2,803 | 2,842 | +1.14% | 2,967,300 | - | -1.04% |
| 08/07 | 2,818 | 2,858 | 2,794 | 2,810 | -0.57% | 3,710,900 | - | -2.19% |
| 08/06 | 2,750 | 2,833 | 2,732 | 2,826 | +2.47% | 3,006,000 | - | -1.6% |
| 08/05 | 2,773 | 2,814 | 2,739 | 2,758 | -0.61% | 3,148,200 | - | -3.87% |
| 08/04 | 2,853 | 2,900 | 2,772 | 2,775 | -4.28% | 4,060,600 | - | -3.31% |
| 08/03 | (IR情報)15:30 2026年度第1四半期決算およびHIV事業に関するアップデート説明資料 |
| 08/03 | (IR情報)15:30 2027年3月期第1四半期決算補足資料 |
| 08/03 | (IR情報)15:30 2027年3月期第1四半期決算短信〔IFRS〕(連結) |
| 08/03 | 2,917 | 2,920 | 2,825 | 2,899 | -0.34% | 2,659,500 | - | +0.98% |
| 07/31 | 2,921 | 2,951 | 2,893 | 2,909 | -4.34% | 3,058,800 | - | +1.54% |
| 07/30 | 3,050 | 3,082 | 2,999 | 3,041 | -0.94% | 3,118,900 | - | +6.4% |
| 07/29 | 2,948 | 3,070 | 2,920 | 3,070 | +5.75% | 3,912,900 | - | +7.76% |
| 07/28 | 2,909 | 2,930 | 2,880 | 2,903 | +0.28% | 2,128,300 | - | +2.25% |
| 07/27 | 2,855 | 2,904 | 2,854 | 2,895 | +1.37% | 1,957,400 | - | +2.12% |
| 07/24 | 2,846 | 2,876 | 2,826 | 2,856 | +0.28% | 1,900,200 | - | +0.88% |
| 07/23 | (IR情報)15:30 譲渡制限付株式報酬としての自己株式の処分の払込完了について |
| 07/23 | 2,877 | 2,885 | 2,824 | 2,848 | -0.97% | 1,989,600 | - | +0.64% |
| 07/22 | 2,876 | 2,887 | 2,842 | 2,876 | -0.83% | 2,151,500 | - | +1.66% |
| 07/21 | 2,919 | 2,926 | 2,870 | 2,900 | +0.83% | 3,007,500 | - | +2.62% |
| 07/17 | 2,858 | 2,929 | 2,849 | 2,876 | +1.16% | 3,508,400 | - | +1.91% |
| 07/16 | 2,848 | 2,872 | 2,831 | 2,843 | +0.07% | 2,218,900 | - | +0.89% |
| 07/15 | 2,915 | 2,915 | 2,810 | 2,841 | -0.28% | 2,431,300 | - | +0.92% |
| 07/14 | 2,832 | 2,874 | 2,820 | 2,849 | +1.1% | 2,084,600 | - | +1.28% |
| 07/13 | 2,837 | 2,837 | 2,806 | 2,818 | -0.53% | 2,070,600 | - | +0.28% |
| 07/10 | 2,865 | 2,865 | 2,803 | 2,833 | -0.07% | 2,194,800 | - | +0.78% |
| 07/09 | 2,872 | 2,893 | 2,814 | 2,835 | -1.36% | 2,418,600 | - | +0.82% |
| 07/08 | 2,955 | 2,959 | 2,861 | 2,874 | -1.2% | 3,303,000 | - | +2.2% |
| 07/07 | 2,926 | 2,958 | 2,899 | 2,909 | -0.48% | 2,914,200 | - | +3.52% |
| 07/06 | 2,892 | 2,930 | 2,871 | 2,923 | +1.88% | 1,916,700 | - | +4.17% |
| 07/03 | 2,889 | 2,941 | 2,851 | 2,869 | +3.09% | 2,854,600 | - | +2.32% |
| 07/02 | 2,776 | 2,805 | 2,731 | 2,783 | +1.87% | 2,776,300 | - | -0.93% |
| 07/01 | 2,689 | 2,789 | 2,688 | 2,732 | -2.04% | 2,703,500 | - | -3.05% |
| 06/30 | 2,813 | 2,817 | 2,764 | 2,789 | -0.61% | 3,453,700 | - | -1.45% |
| 06/29 | 2,770 | 2,835 | 2,767 | 2,806 | +1.85% | 2,918,500 | - | -1.13% |
| 06/26 | 2,740 | 2,767 | 2,716 | 2,755 | +1.32% | 2,409,300 | - | -3.23% |
| 06/25 | 2,800 | 2,808 | 2,719 | 2,719 | -3.62% | 2,915,300 | - | -4.76% |
| 06/24 | (IR情報)17:00 譲渡制限付株式報酬としての自己株式の処分について |
| 06/24 | (IR情報)16:00 資本コストや株価を意識した経営の実現に向けた対応に関するお知らせ |
| 06/24 | 2,810 | 2,837 | 2,785 | 2,821 | +0.04% | 2,475,200 | - | -1.57% |
| 06/23 | 2,838 | 2,850 | 2,800 | 2,820 | +0.28% | 2,447,600 | - | -1.88% |
| 06/22 | 2,780 | 2,812 | 2,771 | 2,812 | +1.15% | 1,742,600 | - | -2.43% |
| 06/19 | (IR情報)14:00 抗新型コロナウイルス(SARS-CoV-2)薬ゾコーバの国内における小児用法・用量の追加承認について |
| 06/19 | 2,783 | 2,822 | 2,760 | 2,780 | -1.87% | 3,411,000 | - | -3.87% |
| 06/18 | (IR情報)13:00 新規抗真菌薬オロロフィムのグローバル第3相臨床試験(OASIS試験)における良好な結果について(速報) |
| 06/18 | 2,855 | 2,866 | 2,820 | 2,833 | 0% | 2,117,600 | - | -2.44% |
| 06/17 | 2,812 | 2,846 | 2,797 | 2,833 | +0.85% | 1,868,500 | - | -2.78% |
| 06/16 | 2,870 | 2,870 | 2,781 | 2,809 | +0.79% | 2,044,800 | - | -3.77% |
| 06/15 | 2,770 | 2,819 | 2,770 | 2,787 | +0.4% | 1,842,400 | - | -5.01% |
| 06/12 | 2,790 | 2,805 | 2,746 | 2,776 | +0.22% | 3,282,900 | - | -5.93% |
| 06/11 | 2,671 | 2,781 | 2,671 | 2,770 | -1% | 2,555,400 | - | -6.64% |
| 06/10 | 2,767 | 2,798 | 2,748 | 2,798 | +1.08% | 2,614,300 | - | -6.17% |
| 06/09 | 2,840 | 2,843 | 2,764 | 2,768 | -2.71% | 3,203,900 | - | -7.58% |
| 06/08 | 2,899 | 2,900 | 2,822 | 2,845 | -0.7% | 2,825,500 | - | -5.51% |
| 06/05 | 2,856 | 2,894 | 2,847 | 2,865 | +1.34% | 2,584,900 | - | -5.29% |
| 06/04 | 2,858 | 2,865 | 2,819 | 2,827 | +0.35% | 2,414,500 | - | -6.79% |
| 06/03 | 2,781 | 2,845 | 2,767 | 2,817 | -0.21% | 2,832,700 | - | -7.46% |
| 06/02 | 2,665 | 2,850 | 2,665 | 2,823 | -1.47% | 4,575,400 | - | -7.62% |
| 06/01 | 3,003 | 3,050 | 2,835 | 2,865 | -4.5% | 3,681,400 | - | -6.56% |
| 06/01 | (IR情報)9:00 抗新型コロナウイルス(SARS-CoV-2)薬エンシトレルビルフマル酸のCOVID-19曝露後発症予防における米国FDAの承認について |
| 05/29 | (IR情報)15:00 オピオイド誘発性便秘症治療薬ナルデメジンの中国における新薬承認取得について |
| 05/29 | 3,000 | 3,040 | 2,993 | 3,000 | +0.1% | 8,183,800 | - | -2.5% |
| 05/28 | 3,073 | 3,088 | 2,996 | 2,997 | -1.12% | 2,915,200 | - | -2.85% |
| 05/27 | 2,984 | 3,072 | 2,956 | 3,031 | +1.27% | 3,583,900 | - | -2.04% |
| 05/26 | 3,025 | 3,054 | 2,993 | 2,993 | -1.19% | 2,644,900 | - | -3.58% |
| 05/25 | 2,982 | 3,043 | 2,975 | 3,029 | +2.33% | 2,739,100 | - | -2.79% |
| 05/22 | 2,954 | 3,019 | 2,951 | 2,960 | -0.7% | 2,661,800 | - | -5.37% |
| 05/21 | 3,041 | 3,071 | 2,972 | 2,981 | -1.78% | 2,214,200 | - | -5.21% |
| 05/20 | 3,032 | 3,105 | 3,027 | 3,035 | +0.23% | 3,502,900 | - | -3.96% |
| 05/19 | 3,071 | 3,086 | 3,019 | 3,028 | -0.69% | 2,752,400 | - | -4.72% |
| 05/18 | 3,079 | 3,108 | 3,031 | 3,049 | -1.01% | 2,454,500 | - | -4.75% |
| 05/15 | 3,025 | 3,113 | 3,016 | 3,080 | +0.13% | 3,069,400 | - | -4.47% |
| 05/14 | 2,989 | 3,076 | 2,957 | 3,076 | +3.29% | 3,312,800 | - | -5.18% |
| 05/13 | 2,812 | 3,011 | 2,747 | 2,978 | -6.09% | 6,495,900 | - | -8.73% |
| 05/12 | (IR情報)15:30 2025年度決算説明資料 |
| 05/12 | (IR情報)15:30 2026年3月期決算補足資料 |
| 05/12 | (IR情報)15:30 2026年3月期決算短信〔IFRS〕(連結) |
| 05/12 | 3,188 | 3,235 | 3,165 | 3,171 | -1.12% | 2,385,000 | - | -3.5% |
| 05/11 | (5%ルール)ウエリントン・マネージメント・カンパニー・エルエ…(3.68%)ウエリントン・マネージメント・ジャパン・ピーティ…(0.69%)ウエリントン・マネージメント・ホンコン・リミテッ…(0.45%)ウエリントン・マネージメント・ヨーロッパ・ゲーエ…(0.4%) |
| 05/11 | 3,177 | 3,216 | 3,137 | 3,207 | +0.94% | 3,007,600 | - | -2.94% |